Skip to main content
SpringerLink
Log in

A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors

  • Living reference work entry
  • First Online:
Handbook of Cancer and Immunology

  • 99 Accesses

Abstract

The last decade has seen an exponential rise in the use of immune checkpoint inhibitors (ICIs). The use of ICIs has given new hope in cancer treatment. At the same time, there are unique side effects related to ICIs which pose a challenge to practicing oncologists. The international societies have laid down recommendations to assist in managing these adverse events (AEs). Among the immune-related adverse events (irAEs), the nervous system is one of the rare sites to be affected. Due to the rarity of irAEs, there is little practical experience among the oncologists. This chapter is a comprehensive review of the neurological irAEs, their clinical presentation, and management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765–772

    Article  CAS  Google Scholar 

  • Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19(8):102586

    Article  CAS  Google Scholar 

  • Athimni S, Slouma M, Dhahri R, Gharsallah I, Metouia L, Louzir B (2021) Tuberculosis infection under anti-TNF alpha treatment. Curr. Drug Saf

    Google Scholar 

  • Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173–182

    Article  Google Scholar 

  • Benesova K, Lorenz HM, Leipe J, Jordan K (2019) How I treat cancer: treatment of rheumatological side effects of immunotherapy. ESMO Open. 4(Suppl 4):e000529

    Google Scholar 

  • Birnbaum J, Bingham CO 3rd. (2014) Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors. Semin Arthritis Rheum 43(5):638–647

    Article  CAS  Google Scholar 

  • Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465

    Article  CAS  Google Scholar 

  • Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768

    Article  CAS  Google Scholar 

  • Burton LB, Eskian M, Guidon AC, Reynolds KL (2021) A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neurooncol Adv 3(Suppl 5):v108–vv20

    Google Scholar 

  • Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T et al (2016) Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186(12):3225–3235

    Article  CAS  Google Scholar 

  • Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B (2019) Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 130(8):1440–1445

    Article  Google Scholar 

  • Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 11:1756286418799864

    Article  Google Scholar 

  • Daxini A, Cronin K, Sreih AG (2018) Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol 37(9):2579–2584

    Article  Google Scholar 

  • Diamanti L, Picca A, Bini P, Gastaldi M, Alfonsi E, Pichiecchio A et al (2021) Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurol Sci

    Google Scholar 

  • Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369

    Article  CAS  Google Scholar 

  • Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing Spectrum. Ann Neurol 87(5):659–669

    Article  Google Scholar 

  • Durães J, Coutinho I, Mariano A, Geraldo A, Macário MC (2019) Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma. Mult Scler 25(7):1005–1008

    Article  Google Scholar 

  • Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neuro-Oncol 137(3):601–609

    Article  CAS  Google Scholar 

  • Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol 21(10):1336–1342

    Article  Google Scholar 

  • Gardin T, Longbrake EE (2021) The role of immune checkpoint therapy in propagating neurologic immune-related adverse events: inducing or “unmasking” autoimmunity? Neurology 96:733–734

    Article  CAS  Google Scholar 

  • Giannoccaro MP, Paolucci M, Zenesini C, Di Stasi V, Donadio V, Avoni P et al (2020) Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis. Neurology 95(13):e1800–e18e6

    Article  CAS  Google Scholar 

  • Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9(7)

    Google Scholar 

  • Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv119–iv42

    Google Scholar 

  • Haugh AM, Probasco JC, Johnson DB (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19(4):479–488

    Article  CAS  Google Scholar 

  • Hines J, Daily E, Pham AK, Shea CR, Nadeem U, Husain AN et al (2021) Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. J Med Case Rep 15(1):124

    Article  Google Scholar 

  • Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65(3):1089–1096

    Article  CAS  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  CAS  Google Scholar 

  • Iwai Y, Terawaki S, Honjo T (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17(2):133–144

    Article  CAS  Google Scholar 

  • Jordan B, Benesova K, Hassel JC, Wick W, Jordan K (2021) How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open 6(6):100317

    Article  CAS  Google Scholar 

  • Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell Death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63

    Article  Google Scholar 

  • Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734–1736

    Article  CAS  Google Scholar 

  • Ledford H (2011) Melanoma drug wins US approval. Nature 471:561

    Article  CAS  Google Scholar 

  • Linnoila J, Pittock SJ (2016) Autoantibody-associated central nervous system neurologic disorders. Semin Neurol 36(4):382–396

    Article  Google Scholar 

  • Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754–766

    Article  CAS  Google Scholar 

  • Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H et al (2015) Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21(4):749–755

    Article  CAS  Google Scholar 

  • Mitoma H, Manto M, Hampe CS (2019) Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges. Curr Neuropharmacol 17(1):33–58

    Article  CAS  Google Scholar 

  • Moicean AD, Popp AM, Sinescu I (2009) Thymoglobulin – new approaches to optimal outcomes. J Med Life 2(3):319–324

    Google Scholar 

  • Mukharesh L, Chwalisz BK (2021) Neuro-ophthalmic complications of immune-checkpoint inhibitors. Semin Ophthalmol 36(4):241–249

    Article  Google Scholar 

  • Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM et al (2017) Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8(42):73312–73328

    Article  Google Scholar 

  • Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141–151

    Article  CAS  Google Scholar 

  • Oliveira MCB, de Brito MH, Simabukuro MM (2020) Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature. Front Neurol 11:538695

    Article  Google Scholar 

  • Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569(7756):428–432

    Article  CAS  Google Scholar 

  • Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M et al (2021) Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 8(3)

    Google Scholar 

  • Psimaras D, Velasco R, Birzu C, Tamburin S, Lustberg M, Bruna J et al (2019) Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S74–s85

    CAS  Google Scholar 

  • Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319

    Article  Google Scholar 

  • Shelly S, Triplett JD, Pinto MV, Milone M, Diehn FE, Zekeridou A et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2(2) fcaa181

    Google Scholar 

  • Smithy JW, Faleck DM, Postow MA (2021) Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events. Clin Cancer Res

    Google Scholar 

  • Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127–1134

    Article  CAS  Google Scholar 

  • Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A (2021) Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Ther Adv Drug Saf 12:20420986211004745

    Article  CAS  Google Scholar 

  • Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17(4):525–535

    Article  Google Scholar 

  • Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23(2):39

    Article  Google Scholar 

  • Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728

    Article  Google Scholar 

  • Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J et al (2018) Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab 103(2):365–369

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

    Kamal Kant Sahu, Nicolas Sayegh & Haoran Li

Authors
  1. Kamal Kant Sahu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Sayegh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haoran Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kamal Kant Sahu .

Editor information

Editors and Affiliations

  1. Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Sweden

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Sahu, K.K., Sayegh, N., Li, H. (2022). A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_346-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80962-1_346-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80962-1

  • Online ISBN: 978-3-030-80962-1

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation